About
Theriva Biologics is a clinical-stage immuno-oncology company developing systemically deliverable oncolytic viruses engineered to selectively kill tumor cells and overcome barriers around solid tumors, aiming to enhance current standard cancer therapies for difficult-to-treat cancers.
Explore Theriva Biologics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.